Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T21:56:45.608Z.
Calculation as of: 2026-10-06T21:56:45.608Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02887d9f7d553dead588493e3d1cc1cda6164751857f77264c258b40fe63259
PE RATIO
N/A
Market Cap
$280.37M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.81M
PE Ratio
N/A
TTM Avg
39.79
3Y Avg
40.81
5Y Avg
32.75
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.54M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $282.64M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | N/A | 46.08 | 46.08 | 46.08 |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | N/A | 6.29 | 6.29 | 6.29 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $288.79M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A | 39.79 | 40.81 | 32.75 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.69
Forward EPS (Est.)
$-0.60
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
